Ann: Response to ASX Price and Volume Query, page-5

First 5 Last

Share
Profile

Follow
Peeteepoo

2,648 Posts.

1573

23/07/19

14:32

Post #: 39651210
Share

Originally posted by Mr.Red: ↑

1. PharmAust is not aware of any information concerning it that has not been announced which, ifknown by some in the market, could explain the recent trading in its securities.The Directors believe the recent trading in its shares is primarily due to the increased awareness inthe market place of PharmAust and the progress of the clinical trials of its primary drug candidate,Monepantel (MPL).In that context, PharmAust draws the attention of the ASX to its announcement on 15 July 2019that it had received ethics approval from the NSW Department of Primary Industry’s Secretary'sAnimal Care & Ethics Committee to recommence Phase II clinical trials in pet owners’ dogs withcancer using its newly formulated tablet.PharmAust also reported that the scaled manufacture of the new GMP quality tablet iscompleted.and anticipates delivery of the tablets from the USA in August/September and thenrecruitment can commence for the Phase II trials shortly thereafter. PharmAust aims to first treatdogs with B-cell lymphoma, the most prevalent canine cancer.The company is also pleased that its wholly owned subsidiary, Epichem Pty Ltd, has continued tobuild contract sales and income activities. On 2 July 2019, PharmAust announced that Epichemhad paid off its debt liability on time for a major state-of-the-art laboratory expansion undertakenEpichem’s revenues have made a significant upturn over the period 2015 to 2018, increasing 38%to $3.02 million in FY18, and forecast to exceed $3.7 million in FY19. Budgeted revenues for FY20are $4.2 million (subject to continuation of existing contracts). With the loan facility repaid the moneysaved on interest and principal will go straight to improving the bottom line.Finally, PharmAust notes that its largest shareholder has increased his holding in PAA from 5.16%to 7.49% and a Form 604 Notice of Change of Interests of Substantial Holder was released on theASX Company Announcements Platform this morning.2. (a) not applicable(b) not applicable(c) not applicable3. PAA is not aware of any other explanation for the recent trading in its securities.PharmAust Limited ABN 35 094 006 023. Suite 39, 1 Freshwater Parade, Claremont, Western AustraliaTel: 08 9202 6814 Fax: 08 9467 6111www.pharmaust.com4. PAA is in compliance with the Listing Rules of ASX including Listing Rule 3.1.5. PAA confirms that the responses to the questions above have been authorised and approved by itsboard.Yours sincerelySam WrightDirector & Company Secretary

Expand

Brilliant response from the Company !!!!

All the Best
Pete

GLTAH

PAA Price at posting: 6.8¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

IRE

Iress runs 'hot' for Wealth Within's stock tips

There are more pages in this discussion • 11 more messages in this thread...

First 5 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change -0.005(2.56%)		Mkt cap ! $92.41M

Open	High	Low	Value	Volume
21.0¢	21.0¢	19.0¢	$165.4K	836.9K

Buyers (Bids)

No.	Vol.	Price($)
8	417395	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	103291	3

View Market Depth

No.	Vol.	Price($)
8	417395	0.190
4	88546	0.185
7	258662	0.180
8	377473	0.175
9	181233	0.170

Price($)	Vol.	No.
0.195	103291	3
0.200	191216	3
0.205	40000	1
0.210	220211	6
0.215	254820	7

Last trade - 16.10pm 01/10/2024 (20 minute delay)

PAA (ASX) Chart

Ann: Response to ASX Price and Volume Query, page-5

Failure to report prompts ASX to impose multiple company suspensions

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Response to ASX Price and Volume Query, page-5

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News